Taysha Gene Therapies, Inc.
TSHA
$6.85
$0.030.44%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 5.49M | -- | 1.99M | 2.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 5.49M | -- | 1.99M | 2.30M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 5.49M | -- | 1.99M | 2.30M |
| SG&A Expenses | 9.68M | 8.83M | 8.28M | 8.60M | 8.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.49M | 33.79M | 34.02M | 28.74M | 23.72M |
| Operating Income | -43.49M | -28.30M | -34.02M | -26.75M | -21.42M |
| Income Before Tax | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M |
| EBIT | -43.49M | -28.30M | -34.02M | -26.75M | -21.42M |
| EBITDA | -43.19M | -28.00M | -33.74M | -26.48M | -21.14M |
| EPS Basic | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 |
| Normalized Basic EPS | -0.07 | -0.04 | -0.06 | -0.05 | -0.05 |
| EPS Diluted | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 |
| Normalized Diluted EPS | -0.07 | -0.04 | -0.06 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 366.63M | 357.32M | 353.31M | 297.99M | 269.31M |
| Average Diluted Shares Outstanding | 366.63M | 357.32M | 353.31M | 297.99M | 269.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |